CoChat

Insights into biopsy-proven cardiac sarcoidosis in patients with heart failure

Open access
Sperry, Brett W., Oldan, Jorge, Hachamovitch, Rory, Tamarappoo, Balaji K. · 2016 · The Journal of Heart and Lung Transplantation
Cited by 31

The DOI matches its Crossref record.

Abstract

Sarcoidosis is a multisystem inflammatory disease of unknown etiology that is characterized histologically by the presence of non-caseating granulomas. It most commonly affects the lungs and thoracic lymph nodes; however, autopsy studies have shown that up to 27% of patients with sarcoidosis have cardiac involvement.1 The diagnosis of cardiac sarcoidosis (CS) is challenging, because specimens from an endomyocardial biopsy (the gold standard) are confirmatory in only 32% of patients.2 Patients diagnosed with CS who present with heart failure symptoms have a worse prognosis than those who present with other symptoms3 and have acceptable long-term outcomes without recurrence after heart transplantation.4 The Heart Rhythm Society (HRS) recommends that patients with extracardiac sarcoidosis proven by biopsy specimen undergo advanced cardiac imaging if they have an abnormal electrocardiogram (ECG), abnormal echocardiogram, or symptoms (palpitations, syncope, or presyncope).5 We sought to determine how well this recommendation performed if applied to our population of patients with CS proven by biopsy specimen who initially presented with heart failure. A retrospective analysis was performed of 27 consecutive patients at the Cleveland Clinic with CS proven by myocardial biopsy specimen from 2002 to 2014. Patients were included with New York Heart Association Functional Classification ≥ II symptoms and a left ventricular ejection fraction of ≤50%. Baseline data were obtained on all patients before cardiac tissue diagnosis, including clinical characteristics, echocardiographic, ECG, and laboratory findings. Positron emission tomography with 18F-fluoro-2-deoxy-D-glucose (FDG-PET) and cardiac magnetic resonance imaging (CMR) were evaluated when available (Table). Table Clinical Characteristics and Japanese Ministry of Health and Welfare Criteria in Patients with Biopsy Specimen– Proven Cardiac Sarcoidosis and Cardiomyopathy Patients were on average in their sixth decade of life and more likely to be Caucasian and male. The ECGs in all patients showed abnormalities, as defined by a complete right or left bundle branch block, axis deviation, ventricular tachycardia, frequent premature ventricular contractions, or abnormal Q waves. Eighteen patients (67%) had class III or IV heart failure symptoms, 16 (59%) had ventricular tachycardia, and 15 (56%) had advanced heart block requiring pacing. All patients met at least 1 criterion needed to warrant further investigation with FDG-PET or CMR based on the HRS consensus statement.5 In contrast, only 8 of 27 patients (30%) met Japanese Ministry of Health and Welfare criteria for CS before cardiac biopsy. Of the 16 patients who underwent FDG-PET, 12 had matching segmental defects in perfusion and FDG and 12 had segments with reduced perfusion and enhanced FDG uptake (“mismatched segments”). All patients had matching or mismatched defects. In addition, the 10 patients who underwent contrast-enhanced CMR had late gadolinium enhancement in a pattern consistent with CS. Fourteen patients (52%) had isolated CS, defined as lack of extracardiac symptoms, diagnostic biopsy specimen, or imaging findings, including CMR and FDG-PET. There were 19 heart transplantations and 5 left ventricular assist devices (LVADs) in the cohort. Of the 5 patients with LVADs, all of whom went on to heart transplantation, 2 had apical core biopsy specimens that were nondiagnostic but were later confirmed to be sarcoidosis after analysis of the explanted heart. Eight of the 19 patients receiving heart transplantation or LVAD (42%) were previously unaware of a diagnosis of systemic or CS until the time of pathologic confirmation. Ten of the 19 heart transplant patients had isolated CS. All patients were maintained on low-dose prednisone after transplantation. There was no recurrence of CS on endomyocardial biopsy specimens in any of the patients after 25,993 total patient follow-up days with an average follow-up of 4.2 years per patient. This analysis highlights several important points regarding CS proven on biopsy specimen in patients presenting with cardiomyopathy. The LVAD apical core was positive in only 3 of the 5 patients who later went on to heart transplantation, highlighting the heterogeneous involvement of sarcoid granulomas in the myocardium as well as the difficulty in obtaining a positive biopsy sample, even in patients with severe cardiomyopathy. Isolated CS was present in 52% of the patients, validating the high prevalence seen in other studies of biopsy specimen–proven CS.3,4 However, this prevalence may be influenced by selection bias, because patients with extracardiac biopsy specimen–proven sarcoidosis are more likely to have a non-invasive evaluation of cardiac involvement. All patients had an abnormal ECG, reduced LVEF, and findings consistent with the diagnosis of CS on multimodality imaging, including CMR and FDG-PET. This corroborates the findings of the recently published HRS consensus statement on the diagnosis of CS in patients presenting with arrhythmias or heart block and suggests that patients with a cardiomyopathy severe enough to have a positive endomyocardial biopsy specimen or warrant advanced heart failure therapies will have findings consistent with the diagnosis on FDG-PET or CMR.5 Given the difficulty in sampling an affected area for a histologic diagnosis, we agree with the HRS guidelines that a non-invasive approach with CMR or PET imaging is favored. Currently, no consensus recommendations exist regarding the diagnosis and screening of CS in patients presenting with non-ischemic cardiomyopathy. Our results add to the small but growing body of literature in this field.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.healun.2015.12.005

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 31

Metadata

Authors
Sperry, B. W., Oldan, J., Hachamovitch, R., & Tamarappoo, B. K.
Venue
The Journal of Heart and Lung Transplantation
Publisher
Elsevier BV
Published
2016-03
Volume
35
Issue
3
Pages
392-393
ISSN
1053-2498 (ISSN-L)
OpenAlex
W2215872709
Cited by
31
References
0
FWCI
2.37
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insights into biopsy-proven cardiac sarcoidosis in patients with heart failure. https://app.cochat.ai/papers/10.1016/j.healun.2015.12.005
The paper
Sperry, B. W., Oldan, J., Hachamovitch, R., & Tamarappoo, B. K. (2016). Insights into biopsy-proven cardiac sarcoidosis in patients with heart failure. The Journal of Heart and Lung Transplantation. https://doi.org/10.1016/j.healun.2015.12.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.